Armata Pharmaceuticals Stock Today
| ARMP Stock | USD 2.72 0.15 5.84% |
Performance0 of 100
| Odds Of DistressOver 68
|
Armata Pharmaceuticals is selling at 2.72 as of the 9th of June 2024; that is 5.84 percent increase since the beginning of the trading day. The stock's last reported lowest price was 2.67. Armata Pharmaceuticals has more than 68 % chance of experiencing financial distress in the next few years of operation. It also generated negative returns for investors over the last 90 days. Equity ratings for Armata Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 10th of May 2024 and ending today, the 9th of June 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 9th of March 2011 | Category Healthcare | Classification Health Care |
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It has a partnership agreement with Merck Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company has 36.15 M outstanding shares of which 767 shares are presently shorted by private and institutional investors with about 0.05 trading days to cover. More on Armata Pharmaceuticals
Moving together with Armata Stock
| 0.8 | ELEV | Elevation Oncology | PairCorr |
| 0.62 | ENVB | Enveric Biosciences | PairCorr |
| 0.79 | EVOK | Evoke Pharma | PairCorr |
| 0.82 | BMY | Bristol Myers Squibb | PairCorr |
Moving against Armata Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Armata Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO Director | Deborah MD | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Armata Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Armata Pharmaceuticals' financial leverage. It provides some insight into what part of Armata Pharmaceuticals' total assets is financed by creditors.
| |||||
Armata Pharmaceuticals (ARMP) is traded on NYSE MKT Exchange in USA. It is located in 5005 McConnell Avenue, Los Angeles, CA, United States, 90066 and employs 66 people. Armata Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 98.34 M. Armata Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 36.15 M outstanding shares of which 767 shares are presently shorted by private and institutional investors with about 0.05 trading days to cover.
Armata Pharmaceuticals currently holds about 36.98 M in cash with (47.42 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.02.
Check Armata Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationArmata Pharmaceuticals shows majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 70.28 percent of Armata Pharmaceuticals outstanding shares that are owned by insiders signifies that they have been buying or selling the stock in recent months in anticipation of some upcoming event.
Check Armata Ownership Details
Armata Pharmaceuticals Historical Income Statement
Armata Stock Against Markets
Armata Pharmaceuticals Corporate Management
| Richard Rychlik | Corporate VP | Profile | |
| MS MD | Chief Officer | Profile | |
| Duane BA | VP Operations | Profile | |
| Steven Martin | Advisor | Profile | |
| Wenyuan Shi | CoFounder Scientist | Profile | |
| Todd MBA | Advisor | Profile |
Already Invested in Armata Pharmaceuticals?
The danger of trading Armata Pharmaceuticals is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Armata Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Armata Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Armata Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Armata Stock Analysis
When running Armata Pharmaceuticals' price analysis, check to measure Armata Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Armata Pharmaceuticals is operating at the current time. Most of Armata Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Armata Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Armata Pharmaceuticals' price. Additionally, you may evaluate how the addition of Armata Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.